Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation
Cambridge Quarterly of Healthcare Ethics – June 27, 2023
Source: OpenAlex
Summary
Psilocybin, an alkaloid and potent hallucinogen, reliably alters consciousness and perception. Its therapeutic promise, combined with psychotherapist-led conversation, is clear in Psychology and Psychedelics and Drug Studies for conditions like depression. Yet, a central question in Cognitive psychology and Complementary and Alternative Medicine Studies remains: are these profound subjective experiences necessary for healing? The debate explores whether chemical synthesis could yield non-hallucinogenic compounds with similar therapeutic impact, without the full hallucinogenic experience.
Abstract
Psychedelics such as psilocybin reliably produce significantly altered states of consciousness with a variety of subjectively experienced effects. These include certain changes to perception, cognition, and affect, 1 which we refer to here as the acute subjective effects of psychedelics. In recent years, psychedelics such as psilocybin have also shown considerable promise as therapeutic agents when combined with talk therapy, for example, in the treatment of major depression or substance use disorder. 2 However, it is currently unclear whether the aforementioned acute subjective effects are necessary to bring about the observed therapeutic effects of psilocybin and other psychedelics. This uncertainty has sparked a lively—though still largely hypothetical—debate on whether psychedelics without subjective effects (“nonsubjective psychedelics” or “non-hallucinogenic psychedelics”) could still have the same therapeutic impact, or whether the acute subjective effects are in fact necessary for this impact to be fully realized. 3 , 4 , 5